CYDY CytoDyn Inc

$CYDY If Natera is shook over the UNPRECEDENTED & STUNNING results, you better believe I bought‼️🥶🥳☘️😝🔥🫡💃🏻

$CYDY What if the patients in the CRC Extention arm,with LL + ICI, respond like the Ladies of Leronlimab ‼️😝🥶🙌🏼 Our Ladies 6 year anniversary is NOV 2026‼️💃🏻

$CYDY Merck dont lose Cytodyn , like you lost revolution and they got a standing ovation without you‼️🥶

$CYDY if the7 patients that are awaiting confirmation of partial response are confirmed… we jump to over 17% ORR. This is TRIPLE the standard of care! And it’s still early! Let that sink in! Buckle up!

$CYDY 11 patients have reached partial response per the trial sites. 4 of those 11 have already been confirmed by the Blinded Independent Central Review (BICR). 7 of the 11 are currently under review. There have been studies done on how often BICR agrees with the trial sites assessment. Everyone here will be glad to know that they agree on the assessment 95% of the time..

$CYDY Dude on Fox Business just said the new GLP-1 from LLY will be top selling drug in history toping 40 to 50 bilion per year in sales.....hmmm, just wait pal, you ain't seen nutting yet.

$CYDY every time i do a search for Leronlimab for the last week. 2 sponsored Merck things pop up top. Now i dont care if its merck. I kinda hope they lose out to j&j or lilly or roche. But merck is becoming connected i guess from message board chatter or something.

$CYDY At MINIMUM, Leronlimab is going to become part of SOC combination regiments, across all stages, of every indication she enters @ minimum..... ...

$CYDY I would venture to guess by timing, the 7 patients awaiting confirmation are 700. Our 700 numbers can really be astonishing. Remember, 700 did not even start enrolling until January and the majority were enrolled in March and April at the end

$CYDY Mr. Hoffman, you are stepping into the building of a world-wide, conglomerate The most giving to humanity, that has ever been seen. ...

$CYDY I can wait another year for millions and millions more 😉 more confident in ever that once this data gets rolled out throughout 2027 it’s going to be bigger than we think

$CYDY Remembe, Dr Jay said the plan was to deliver a package to the FDA for Breakthough Designation by the end of the year. That should move the needle...

$CYDY Here is why smart money is buying right now: Leronlimab is universally safe, with thousands of dosed patients and ZERO SAE's. We are running a trial on the DEADLIEST FORM OF CANCER FOR PATIENTS UNDER 50. People under 50 are what? PEAK INCOME TAX PAYERS. We show ANY ORR IMPROVEMENT over just Lonsurf and Avastin, drugs that are doing $700,000,000+ in revenue, we get Breakthrough. You think the FDA doesn't want to help patients when the drug has 0 SAE's and is well tolerated, showing improvement? Dr. Kasi himself has 2 patients taking Keytruda now as well and 3 other patients are doing so well they recommend surgery. DO YOU KNOW HOW RARE THAT IS? And you have people shorting this stock and talking crap about the company online. You know how big a POS you have to be to do that? Like I said....smart money is investing.

$CYDY The "cost discounts" & "fully funded" -- CYTODYN, Leronlimab & HUMANITY say --- THANK YOU !!! Jan 2024, Cytodyn only $2M in the bank. Zero active trials or programs, etc.. Q4 2026, LL has the most significant development trial & eAP programs, in history, of more than 20 combined. All due to the many, many cost discount AND fully funding collaborators LL, IS, on that Precipice of making history via unprecedented mCRC results & filing an FDA trial Registrional request WE, know it's barely only the begging.....& what a way to start WOW !! ..

$CYDY Gonna keep buying as soon as I saw those results. If ASCO results signal gonna keep going.

$CYDY 🔥 86% median reduction in circulating tumor DNA (ctDNA) by Week 2 in 28 evaluable patients. ✅ 100% CCR5 expression across 91 evaluable tumor samples. ✅ 66 patients enrolled across 7 clinical sites. ✅ Strong safety profile: No leronlimab-related serious (Grade 3+) adverse events or treatment discontinuations among 32 patients with available safety data. 📈 Statistically significant improvements in molecular residual disease reductions versus comparator regimens (p=0.0005 and p=0.0006). These are promising early signals supporting leronlimab’s potential in cancer treatment. Clinical response and survival data are still needed, but the science continues to progress. $CYDY is building a compelling oncology story.

$CYDY Hoping for a juicy PR Monday morning with more clarity on the numbers and any additional information Dr. Weinberg disclosed at ESMO (whether on purpose or by "accident"). It's pretty crummy that with all the awesome recent information, the Latest CYDY News section on the right column still shows "CYDY Stock Falls Despite Positive Cancer Study Data..." They need to fix that with recent headlines or something.

$CYDY we are going to win bigger than we even know. The world will be dumbfounded. Watch. I'm not predicting the when just the results. January asco is gonna be fire.

$CYDY $NTRA No way they didn’t mention us and Leronlimab during that process. Great work Natera! Maybe they even showed them a lil something 😉🤑

$CYDY To all new investors: The science is indisputable! Funded through mid-2027. Hoffmann will get it done! Perhaps even sooner. Have patience—even if it’s difficult.